このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Rezolute 過去の業績

過去基準チェック /06

Rezoluteの収益は年平均-16.7%で減少しているが、Biotechs業界はgrowingで15.5%年平均の収益となった。

主要情報

-16.7%

収益成長率

64.9%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	n/a
株主資本利益率	-82.1%
ネット・マージン	n/a
前回の決算情報	31 Mar 2024

Recent updates

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

May 22

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12

収支内訳

Rezolute の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:RZLT 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
31 Mar 24	-58	14	47
31 Dec 23	-57	14	49
30 Sep 23	-56	14	48
30 Jun 23	-52	13	43
31 Mar 23	-48	12	41
31 Dec 22	-44	11	36
30 Sep 22	-43	10	34
30 Jun 22	-41	10	32
31 Mar 22	-38	9	28
31 Dec 21	-31	9	23
30 Sep 21	-25	9	18
30 Jun 21	-21	8	15
31 Mar 21	-18	7	13
31 Dec 20	-19	6	13
30 Sep 20	-19	5	14
30 Jun 20	-20	6	14
31 Mar 20	-20	6	14
31 Dec 19	-37	7	25
30 Sep 19	-34	7	21
30 Jun 19	-33	7	19
31 Mar 19	-42	7	24
31 Dec 18	-25	8	12
30 Sep 18	-27	8	14
30 Jun 18	-30	9	17
31 Mar 18	-24	10	13
31 Dec 17	-27	9	14
30 Sep 17	-27	9	14
30 Jun 17	-24	8	12
31 Mar 17	-27	6	12
31 Dec 16	-22	5	11
30 Sep 16	-21	5	10
30 Jun 16	-21	5	9
31 Mar 16	-14	5	9
31 Dec 15	-14	5	8
30 Sep 15	-12	5	7
30 Jun 15	-11	6	5
31 Mar 15	-10	6	3
31 Dec 14	-12	7	2
30 Sep 14	-11	6	0
30 Jun 14	-10	5	0
31 Mar 14	-9	4	0
31 Dec 13	-8	6	0
30 Sep 13	-7	6	0

質の高い収益: RZLTは現在利益が出ていません。

利益率の向上: RZLTは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: RZLTは利益が出ておらず、過去 5 年間で損失は年間16.7%の割合で増加しています。

成長の加速: RZLTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: RZLTは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: RZLTは現在利益が出ていないため、自己資本利益率 ( -82.15% ) はマイナスです。

Rezolute 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Recent updates

Rezolute, Inc. announced that it expects to receive $6 million in funding

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $59.99625 million.

New major risk - Share price stability

Price target increased by 9.4% to US$10.57

Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc., Annual General Meeting, May 16, 2024

Director recently bought US$70k worth of stock

Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

Chief Financial Officer recently bought US$67k worth of stock

Price target increased by 9.0% to US$8.50

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Now 29% overvalued after recent price rise

Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer

Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema

Rezolute Receives a Written Notice from the Listing Qualifications Department of Nasdaq Stock Market

New minor risk - Shareholder dilution

New minor risk - Share price stability

Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

New major risk - Revenue and earnings growth

Price target decreased by 30% to US$7.80

Rezolute, Inc. Provides an Update on Its Clinical Development Plans for RZ358

Rezolute, Inc. to Report Q3, 2023 Results on May 11, 2023

Price target decreased by 7.9% to US$11.60

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute, Inc. Announces Initiation of A Phase 2 Study of Rz402 in Patients with Diabetic Macular Edema

High number of new and inexperienced directors

Price target decreased to US$12.60

Rezolute GAAP EPS of -$0.37

Rezolute, Inc. Promotes Brian Roberts to Chief Medical Officer

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased to US$19.20

Rezolute, Inc. has completed a Follow-on Equity Offering in the amount of $117.587085 million.

Rezolute, Inc. Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Rezolute, Inc., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Rezolute, Inc Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Rezolute, Inc. Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies At ESPE 2021

Rezolute, Inc. Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Rezolute, Inc. Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

Price target decreased to US$26.50

High number of new and inexperienced directors

Price target decreased to US$27.00

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute, Inc. Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema

Rezolute shares rise on positive topline results from RZ402 eye disease trial

Rezolute, Inc. Announces Board Appointments

New 90-day low: US$11.98

Rezolute, Inc. Announces Phase 2B Study of RZ358 Continues to Enroll Congenital Hyperinsulinism (HI) Patients Worldwide

Rezolute Announces Initiation of Phase 1 Study of RZ402 for the Treatment of Diabetic Macular Edema

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

New 90-day low: US$12.94

Rezolute, Inc. Announces Resignation of Jung-Hee Lim as a Member of the Board of Directors, Audit Committee and Compensation Committee

Price target raised to US$31.50

Rezolute, Inc. Announces CFO Changes

Rezolute, Inc. announced that it expects to receive $40.92 million in funding from BVF Partners LP, Citadel Advisors LLC, and other investors

Rezolute, Inc. announced delayed annual 10-K filing

Rezolute Announces Publication of Rz402 Data in Diabetic Macular Edema (Dme) in Investigative Ophthalmology & Visual Science

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06